Johnson & Johnson’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Johnson & Johnson’s Portfolio SLGC Stock Details SLGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-281,052	Closed	-$711K	–	24
2023 Q4	$711K	Hold	281,052	–	–	0.02%	18
2023 Q3	$672K	Hold	281,052	–	–	0.25%	19
2023 Q2	$649K	Hold	281,052	–	–	0.2%	17
2023 Q1	$717K	Hold	281,052	–	–	0.23%	16
2022 Q4	$705K	Hold	281,052	–	–	0.21%	16
2022 Q3	$815K	Hold	281,052	–	–	0.24%	16
2022 Q2	$1.27M	Hold	281,052	–	–	0.32%	17
2022 Q1	$2.25M	Hold	281,052	–	–	0.43%	15
2021 Q4	$3.27M	Hold	281,052	–	–	0.37%	16
2021 Q3	$3.48M	Buy	+281,052	New	+$3.17M	0.31%	16

Johnson & Johnson's SLGC Position: Q1 2024 in Review

Johnson & Johnson sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 281,052 shares — an estimated $711K sold.

Johnson & Johnson first reported a position in SLGC in Q3 2021 and held it in 10 quarters. The position peaked at $3.48M in Q3 2021. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

Johnson & Johnson reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
Johnson & Johnson sold 281,052 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $711K.
Johnson & Johnson first reported a position in SomaLogic, Inc. Class A Common Stock in Q3 2021 and held it in 10 quarters.
Johnson & Johnson's SomaLogic, Inc. Class A Common Stock position peaked at $3.48M in Q3 2021.
0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Johnson & Johnson's 13F filing for Q1 2024, filed 10 May 2024.